Article
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
Oncogene - 1 Jan 2019
Wang Edina, Sorolla Anabel, Cunningham Paula T, Bogdawa Heique M, Beck Samuel, Golden Emily, Dewhurst Robert E, Florez Laura, Cruickshank Mark N, Hoffmann Katrin, Hopkins Richard M, Kim Jonghwan, Woo Andrew J, Watt Paul M, Blancafort Pilar
Abstract excerpt
Overexpression of MYC oncogene is highly prevalent in many malignancies such as aggressive triple-negative breast cancers (TNBCs) and it is associated with very poor outcome. Despite decades of research, attempts to effectively inhibit MYC, particularly with small molecules, still remain challenging due to the featureless nature of its protein structure. Herein, we describe the engineering of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.